Exopolysaccharide from Lacticaseibacillus rhamnosus induces IgA production in airways and alleviates allergic airway inflammation in mouse model
© 2023 Wiley-VCH GmbH..
The currently observed high prevalence of allergic diseases has been associated with changes in microbial exposure in industrialized countries. Defined bacterial components represent a new strategy for modulating the allergic immune response. We show that intranasal administration of exopolysaccharide (EPS) isolated from Lacticaseibacillus (L.) rhamnosus LOCK900 induces TGF-β1, IgA, and regulatory FoxP3+ T-cells in the lungs of naïve mice. Using the ovalbumin mouse model, we demonstrate that intranasal administration of EPS downregulates the development of allergic airway inflammation and the Th2 cytokine response in sensitized individuals. At the same time, EPS treatment of sensitized mice, similar to EPS-induced responses in naïve mice, significantly increased the level of total, OVA-specific, and also bacteria-specific IgA in bronchoalveolar lavage and the number of IgA-producing B-cells in the lung tissue of these mice. Thus, EPS derived from L. rhamnosus LOCK900 can be considered a safe candidate for preventing the development of allergic symptoms in the lungs of sensitized individuals upon exposure to an allergen.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:53 |
|---|---|
| Enthalten in: |
European journal of immunology - 53(2023), 7 vom: 19. Juli, Seite e2250135 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Srutkova, Dagmar [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
9006-59-1 |
|---|
| Anmerkungen: |
Date Completed 17.07.2023 Date Revised 20.12.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/eji.202250135 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM356805867 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM356805867 | ||
| 003 | DE-627 | ||
| 005 | 20231227134723.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/eji.202250135 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1233.xml |
| 035 | |a (DE-627)NLM356805867 | ||
| 035 | |a (NLM)37177812 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Srutkova, Dagmar |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Exopolysaccharide from Lacticaseibacillus rhamnosus induces IgA production in airways and alleviates allergic airway inflammation in mouse model |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 17.07.2023 | ||
| 500 | |a Date Revised 20.12.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 Wiley-VCH GmbH. | ||
| 520 | |a The currently observed high prevalence of allergic diseases has been associated with changes in microbial exposure in industrialized countries. Defined bacterial components represent a new strategy for modulating the allergic immune response. We show that intranasal administration of exopolysaccharide (EPS) isolated from Lacticaseibacillus (L.) rhamnosus LOCK900 induces TGF-β1, IgA, and regulatory FoxP3+ T-cells in the lungs of naïve mice. Using the ovalbumin mouse model, we demonstrate that intranasal administration of EPS downregulates the development of allergic airway inflammation and the Th2 cytokine response in sensitized individuals. At the same time, EPS treatment of sensitized mice, similar to EPS-induced responses in naïve mice, significantly increased the level of total, OVA-specific, and also bacteria-specific IgA in bronchoalveolar lavage and the number of IgA-producing B-cells in the lung tissue of these mice. Thus, EPS derived from L. rhamnosus LOCK900 can be considered a safe candidate for preventing the development of allergic symptoms in the lungs of sensitized individuals upon exposure to an allergen | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Allergic airway inflammation | |
| 650 | 4 | |a Exopolysaccharide | |
| 650 | 4 | |a IgA antibody | |
| 650 | 4 | |a Immunomodulation | |
| 650 | 4 | |a Lacticaseibacillus | |
| 650 | 7 | |a Immunoglobulin A |2 NLM | |
| 650 | 7 | |a Ovalbumin |2 NLM | |
| 650 | 7 | |a 9006-59-1 |2 NLM | |
| 700 | 1 | |a Kozakova, Hana |e verfasserin |4 aut | |
| 700 | 1 | |a Novotna, Tereza |e verfasserin |4 aut | |
| 700 | 1 | |a Gorska, Sabina |e verfasserin |4 aut | |
| 700 | 1 | |a Hermanova, Petra Petr |e verfasserin |4 aut | |
| 700 | 1 | |a Hudcovic, Tomas |e verfasserin |4 aut | |
| 700 | 1 | |a Svabova, Tereza |e verfasserin |4 aut | |
| 700 | 1 | |a Sinkora, Marek |e verfasserin |4 aut | |
| 700 | 1 | |a Schwarzer, Martin |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of immunology |d 1971 |g 53(2023), 7 vom: 19. Juli, Seite e2250135 |w (DE-627)NLM000108723 |x 1521-4141 |7 nnns |
| 773 | 1 | 8 | |g volume:53 |g year:2023 |g number:7 |g day:19 |g month:07 |g pages:e2250135 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/eji.202250135 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 53 |j 2023 |e 7 |b 19 |c 07 |h e2250135 | ||